Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma
Open Access
- 1 September 2011
- journal article
- Published by Informa UK Limited in Small GTPases
- Vol. 2 (5), 289-292
- https://doi.org/10.4161/sgtp.2.5.17814
Abstract
BRAF and RAS are often mutated in cutaneous melanoma and both mutations stimulate the MAPK pathway. However the biological consequences of BRAF and NRAS mutations are different because when RAS is mutated in melanoma, cells use CRAF rather than BRAF to activate MEK / ERK. The mechanism of this BRAF to CRAF isoform switching in response to oncogenic RAS has recently been described. Activation of the MAPK pathway, which results from a mutation of NRAS, induces phosphorylation of BRAF on serine 151 by ERK which prevents its binding to NRAS. To circumvent this negative feedback inhibition of BRAF, melanoma cells containing a mutation of RAS use CRAF to activate MEK / ERK. However, because the cAMP pathway in melanocytes constitutively inhibits CRAF, RAF isoform switching in melanoma is accompanied by an inhibition of the cAMP pathway. This inhibition is due to an increase in phosphodiesterase activity, which degrades cAMP thereby preventing inhibition of CRAF by PKA. These data highlight the importance of CRAF downstream of oncogenic Ras in tumor development.Keywords
This publication has 34 references indexed in Scilit:
- Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf SignalingMolecular and Cellular Biology, 2010
- Fifteen-year quest for microphthalmia-associated transcription factor target genesPigment Cell & Melanoma Research, 2009
- Phosphodiesterase-4 inhibition in COPDThe Lancet, 2009
- Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body siteMolecular Oncology, 2007
- In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP SignalingCancer Research, 2006
- Wild-Type and Mutant B-RAF Activate C-RAF through Distinct Mechanisms Involving HeterodimerizationMolecular Cell, 2005
- Mutations of C-RAF Are Rare in Human Cancer because C-RAF Has a Low Basal Kinase Activity Compared with B-RAFCancer Research, 2005
- Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathwaysThe FEBS Journal, 2005
- Compartmentalisation of phosphodiesterases and protein kinase A: opposites attractFEBS Letters, 2005
- Guilty as chargedCancer Cell, 2004